Zobrazeno 1 - 10
of 244
pro vyhledávání: '"ACK1"'
Autor:
Jaeyoon Kim, Jang Ho Joo, Juhyun Kim, Heena Rim, Jae young Shin, Yun-Ho Choi, Kyoungin Min, So Young Lee, Seung-Hyun Jun, Nae-Gyu Kang
Publikováno v:
Current Issues in Molecular Biology, Vol 46, Iss 10, Pp 11207-11219 (2024)
Platycladus orientalis is a traditional oriental herbal medicinal plant that is widely used as a component of complex prescriptions for alopecia treatment in Eastern Asia. The effect of PO on hair growth and its underlying mechanism, however, have no
Externí odkaz:
https://doaj.org/article/e8cbeaa7d28d469a87f171c3e58725d8
Autor:
Stephanie Guillet, Tomi Lazarov, Natasha Jordan, Bertrand Boisson, Maria Tello, Barbara Craddock, Ting Zhou, Chihiro Nishi, Rohan Bareja, Hairu Yang, Frederic Rieux-Laucat, Rosa Irene Fregel Lorenzo, Sabrina D Dyall, David Isenberg, David D'Cruz, Nico Lachmann, Olivier Elemento, Agnes Viale, Nicholas D Socci, Laurent Abel, Shigekazu Nagata, Morgan Huse, W Todd Miller, Jean-Laurent Casanova, Frédéric Geissmann
Publikováno v:
eLife, Vol 13 (2024)
Systemic lupus erythematosus (SLE) is an autoimmune disease, the pathophysiology and genetic basis of which are incompletely understood. Using a forward genetic screen in multiplex families with SLE, we identified an association between SLE and compo
Externí odkaz:
https://doaj.org/article/bbeacfc654b64900aa3479d5ae42195e
Autor:
Jinhong Zhu, Kui Cao, Meng Zhao, Keru Ma, Xiangyu Jiang, Yuwen Bai, Xiaodong Ling, Jianqun Ma
Publikováno v:
Molecular Medicine, Vol 29, Iss 1, Pp 1-21 (2023)
Abstract Background Activated Cdc42-associated kinase 1 (ACK1) is a promising druggable target for cancer, but its inhibitors only showed moderate effects in clinical trials. The study aimed to investigate the underlying mechanisms and improve the an
Externí odkaz:
https://doaj.org/article/e20f85885d614674838f07016a61b49c
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-12 (2022)
Abstract Activated Cdc42-associated kinase 1 (ACK1), a kind of tyrosine kinase, is considered to be an oncogene in many cancers, and it is likely to become a potential target for cancer treatment. We found that the expression of the ACK1 gene in colo
Externí odkaz:
https://doaj.org/article/6dae8b60635748928e5eb15b82bd98f5
Publikováno v:
FEBS Open Bio, Vol 11, Iss 6, Pp 1579-1592 (2021)
Activated Cdc42‐associated kinase 1 (ACK1), a widely expressed nonreceptor tyrosine kinase, is often amplified in cancer and has been shown to interact with Cell division cycle 42 (Cdc42), Epidermal growth factor receptor (EGFR), and several other
Externí odkaz:
https://doaj.org/article/e93a338f552f44da99b0145b8e1bf6fd
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Toll-like receptors (TLRs) are the first line of defense in the immune system, whose activation plays a key role in the pathogenesis of inflammation and autoimmunity. TLRs can activate a variety of immune cells such as macrophages and dendritic cells
Externí odkaz:
https://doaj.org/article/bf429ce439b14123b8b7c6f68950ec30
Autor:
Ruby Srivastava
Publikováno v:
Frontiers in Chemistry, Vol 10 (2022)
Activated Cdc42-associated kinase 1 (ACK1/TNK2) has a significant role in cell endocytosis, survival, proliferation, and migration. Mutations in ACK1 are closely associated with the occurrence and development of cancers. In this work, a conceptual de
Externí odkaz:
https://doaj.org/article/7b2228257eee42b09976d348ffe03499
Autor:
Tao Zhang, Rong Qu, Shingpan Chan, Mengzhen Lai, Linjiang Tong, Fang Feng, Hongyu Chen, Tingting Song, Peiran Song, Gang Bai, Yingqiang Liu, Yanan Wang, Yan Li, Yi Su, Yanyan Shen, Yiming Sun, Yi Chen, Meiyu Geng, Ke Ding, Jian Ding, Hua Xie
Publikováno v:
Molecular Cancer, Vol 19, Iss 1, Pp 1-15 (2020)
Abstract Background Non-small cell lung cancer (NSCLC) patients with activating EGFR mutations initially respond to first-generation EGFR inhibitors; however, the efficacy of these drugs is limited by acquired resistance driven by the EGFR T790M muta
Externí odkaz:
https://doaj.org/article/617b628cf3bb46c99c53ec5a4fe4eba6